|
Criteria for Surveillance of Small Renal Mass Examined - Doctors Lounge |
 |
 |
|
Active surveillance of patients with small renal masses is driven by a tumor size less than 3 cm, poor performance score, and an endophytic lesion, among other patient, tumor, and surgeon characteristics, according to research published in the May issue of Urology.
MONDAY, May 7 (HealthDay News) -- Active surveillance of patients with small renal masses is driven by a tumor size less than 3 cm, poor performance score (PS), and an endophytic lesion, among other patient, tumor, and surgeon characteristics, according to research published in the May issue of Urology.
Bruce L. Jacobs, M.D., of the University of Michigan Health System in Ann Arbor, and colleagues conducted a study of 204 consecutive patients with a clinical stage T1 renal mass to evaluate which demographic and clinical characteristics influenced a physician's decision to recommend active surveillance of a patient's renal mass compared with treatment.
The researchers found that, overall, 36 percent of patients underwent active surveillance, and 64 percent were treated for their small renal mass. Demographic and clinical characteristics found more often in those who underwent active surveillance included being located more than 60 miles from a hospital; having an Eastern Cooperative Oncology Group (ECOG) PS of ?2; tumor size and multifocality; the endophytic nature of the lesion; and whether open, laparoscopic, or robotic surgical methods were used by the patient's physician. Neither baseline glomerular filtration rate nor Charlson comorbidity index played a significant role in the decision to pursue active surveillance.
"Patient, tumor, and surgeon characteristics all influence active surveillance for small renal masses. According to the sensitivity analyses, active surveillance was driven by tumor size <3 cm, poor performance status (i.e., ECOG PS of ?2), and an endophytic lesion," the authors write.
Abstract
Full Text (subscription or payment may be required)
 Copyright © 2012 HealthDay. All rights reserved.
Submit your opinion:
|
|
Sixth Annual Tour DaVita Coming to Iowa - MarketWatch (press release) |
|
|
|
DENVER, May 07, 2012 (BUSINESS WIRE) -- DaVita Inc.
/quotes/zigman/268700/quotes/nls/dva DVA
+0.32%
, a leading provider of kidney care services that is committed to improving the quality of life for those diagnosed with chronic kidney disease (CKD), today announces that the sixth annual Tour DaVita(R) -- a three-day, 250-mile bike ride to raise awareness and funds for the fight against kidney disease -- will kick off September 15 at Wilder Park in Allison, Iowa.
Tour DaVita, which features participation by more than 400 DaVita teammates, physicians, family members and friends, has the following itinerary for 2012:
Sept. 16 -- Allison to Independence Sept. 17 -- Independence to Manchester Sept. 18 -- Manchester to Monticello
Along the way, riders will pass through Clarksville, Shell Rock, Waverly, Readlyn and Fairbank on Day 1; Aurora, Lamont, Dundee, Arlington, Volga and Strawberry on Day 2; and Hopkinton, Worthington, Cascade and Canton on Day 3.
"Tour DaVita is much more than just a bike ride for charity -- it's an opportunity for riders from all across the United States to explore a new corner of this great country," said Steve Priest, chief wisdom officer at DaVita and director of the event. "In researching a location for this year's tour, we simply couldn't resist the bicycle-friendly vibe for which Iowa is becoming increasingly famous."
To participate in Tour DaVita, riders will each raise a minimum of $750 to $2,000 in donations and pay their own travel expenses. Their individual fundraising combined with donations from DaVita(R) and other corporate sponsorship is expected to contribute more than $700,000 to Bridge of Life -- DaVita Medical Missions(TM), an independent nonprofit organization committed to helping improve kidney health and save lives by bringing treatment, education and hope to underserved communities around the world.
Tour DaVita, which is organized by Backroads, the world's #1 active travel company(TM), has previously taken place in Tennessee/Alabama (2007), Wisconsin (2008), Michigan (2009), Washington State (2010) and Connecticut/New York/Massachusetts (2011).
For more information about the sixth annual Tour DaVita, please visit
www.tourdavita.org . For more information about Bridge of Life -- DaVita Medical Missions, please visit
http://www.bridgeoflifemm.org . For more information on Backroads, please visit
http://www.backroads.com .
DaVita and Tour DaVita are registered trademarks of DaVita Inc. All other trademarks are the property of their respective owners.
About Bridge of Life
Bridge of Life -- DaVita Medical Missions is a 501(c)(3) nonprofit organization whose mission is to help those in underserved areas around the world receive kidney care not readily available to them. As of April 23, 2012, Bridge of Life has conducted 24 Medical Missions in 7 countries, installed or repaired 124 dialysis machines, trained more than 230 kidney care professionals, and increased the capacity of clinics to provide an estimated 70,928 treatments to approximately 682 additional individuals per year. For more information about the organization, please visit
www.bridgeoflifemm.org .
About DaVita
DaVita Inc., a Fortune 500(R) company, is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients' quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of March 31, 2012, DaVita operated or provided administrative services at 1,841 outpatient dialysis centers located in the United States serving approximately 145,000 patients. The company also operated 15 outpatient dialysis centers located in three countries outside the United States. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company's leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit
www.davita.com .
SOURCE: DaVita Inc.
DaVita Inc.
Media:
Vince Hancock, 303-405-2272
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Copyright Business Wire 2012
/quotes/zigman/268700/quotes/nls/dva
US
: U.S.: NYSE
$
84.65
+0.27
+0.32%
|
|
|
Targeted Therapies Drive the Global Renal Cell Carcinoma (RCC) Drugs Market ... - San Francisco Chronicle (press release) |
|
|
|
GIA announces the release of a comprehensive global report on the Kidney Cancer Drugs markets. The global market for Renal Cell Carcinoma (RCC) Drugs is forecast to reach $3.03 billion by the year 2017, driven by the growing preference for targeted therapies in the treatment of RCC. Additionally, growth is also expected to stem from the introduction of new emerging therapies, increased use of combination therapies, and introduction of other drug classes, such as mTOR inhibitors.
San Jose, California (PRWEB) May 07, 2012
Follow us on LinkedIn - Regardless of being a smaller segment in the overall oncology market, kidney cancer emerged as a key area of research and development, and attracted significant investments from various pharmaceutical and biotechnology majors. Kidney cancer market, for several years, lacked adequate treatment options, with patients being mainly treated with traditional therapies, such as Immunotherapy and Palliative care. Since most of the kidney cancer cases are diagnosed at a stage where they cannot be treated through surgical techniques, targeted therapies are finding increased use for the treatment of kidney cancer. Further, given the fact that kidney cancer is resistant to traditional treatment modalities, such as chemotherapy and radiation therapy, there exists significant potential for targeted therapies, in the years to come.
Among the various types of kidney cancers, Renal Cell Carcinoma (RCC) is the predominant type of kidney cancer, representing nearly 80% of the population affected from kidney cancer. Of all the targeted therapeutic options available for advanced RCC, Pfizer's Sutent has transpired to show significant potential for the treatment of the disease, and demonstrated superior efficacy compared to the traditional standard treatment of Interleukin-2 and Interferon-alpha. However, going forwards, it is estimated that GlaxoSmithKline's Votrient could threaten the dominance of Pfizer's Sutent, the long-established leader in the global RCC drugs market. Also, despite the fact that Multikinase Inhibitors dominate the RCC drugs market, growth in the future is expected to mainly emanate from other drug classes, specifically mTOR inhibitors.
With the global incidence of kidney cancer on the rise, the United States and Europe leads the global market for RCC drugs, as stated by the new market research report on Kidney Cancer Drugs. Historically, the incidence and prevalence of kidney cancer in the US has been lower in comparison to the other parts of the world. However, the incidence has been increasing constantly over the recent years, due to a rise in the number of incidentally diagnosed cases of kidney cancer. Accounting for a major share of the market, the US constitutes the world's largest market for RCC drugs. Growth is expected to mainly emanate from the Asia-Pacific market, which is forecast to register a CAGR of more than 14% during the analysis period. In terms of therapeutic classes, Multikinase Inhibitors dominate the RCC drugs market globally.
Major players profiled in the report include AVEO Pharmaceuticals, Bayer, Bristol-Myers Squibb Co, Onyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Merck-Serono, Novartis AG, Pfizer Inc., WILEX AG, among others.
The research report titled "Kidney Cancer Drugs: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of the kidney cancer drugs market, including the Renal Cell Carcinoma (RCC) market; the disease overview, symptoms, causes, and diagnosis; an overview of the presently available therapeutic classes, including multi-kinase inhibitors, mTOR, and others; the recent product approvals, the pipeline drugs, the key corporate initiatives, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for kidney cancer drugs market for the years 2008 through 2017 for the following geographic markets - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Key therapeutic classes analyzed include Multikinase Inhibitors, and Other Therapeutics Classes (which include Immunomodulators; mTOR Inhibitors; and Other Emerging Drug Classes).
For more details about this comprehensive market research report, please visit -
www.strategyr.com/Kidney_Cancer_Drugs_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Follow us on LinkedIn
Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: www.StrategyR.com/
###
For the original version on PRWeb visit: www.prweb.com/releases/prwebkidney_cancer_drugs/renal_cell_carcinoma_drug/prweb9480916.htm
|
|
Lough Fea walk helps raise funds for renal clinic - Mid Ulster Mail |
|
|
|
Published on Monday 7 May 2012 13:59
A SPONSORED walk around Lough Fea has raised more than £1,500 for the Renal Transplant Clinic at Antrim Area Hospital.
The event was organised by Nicole Clements whose brother, Lee, makes use of the clinic after having a kidney transplant in Belfast City Hospital.
Nicole was helped by three friends from the Northern Regional College in Magherafelt, Laura Bradley, Anne Bradley, and Kathyrn Shaw.
They would like to thank everyone who donated towards the success of the event, especially the following donors:
Dittys Bakery, Off the Diamond, ‘Kennys’ Highfield, Stephen Moffett, Parkmore Roofing, K9 Bonus, Freshways, Gerard Flowers, Tops and Bottoms, Kennys, The Brown Bag, Hair, Sizzlers, Cuddys.
Wattersons Family Butcher, Home Essentials, Lawrences Cake Shop, Sportique, John Barfoot Chartered Certified Accountant, JB Tyres, Jauntys Diner, Toners, Sarah Jane Boutique, O’Brien’s Chemist.
Homecare Plumbing, McAllinden Meats, Bellissima, Nosh Cafe, House of Flowers, Diamond Fish Bar, Dice, Nichols Menswear, Carmel McGuigan, E. Lennox Paint and Paper, McGlaughlins Chemist.
Auto Electrics (Stranaer), Clean and Gleam, Quality Meats, Coagh, Leighs Chippy, Coagh, Coagh Pharmacy, Unconditional Hair, Cookstown.
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
Email to a friend
Print this page
